Added to YB: 2024-02-21
Pitch date: 2024-02-20
BPMC [bullish]
Blueprint Medicines Corporation
+43.73%
current return
Author Info
No bio for this author
Company Info
Blueprint Medicines Corporation operates as a global biopharmaceutical company that develops medicines for genomically defined cancers, blood disorders, and allergy/inflammation in the United States and internationally.
Market Cap
$8.4B
Pitch Price
$90.07
Price Target
N/A
Dividend
N/A
EV/EBITDA
-60.94
P/E
-52.77
EV/Sales
14.58
Sector
Biotechnology
Category
growth
Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
BPMC +64% since buy rec. Ayvakit for ISM gaining traction, peak rev est. $2B. 2023 sales $204M, 2024 proj $360-390M. Q4 net rev +$71M YoY. EV $5.5B, strong balance sheet w/ $711M liquid assets vs $215M liabilities. Pos sentiment, $5.5B mkt cap. Strong buy on Ayvakit success & financials despite burn rate.
Read full article (4 min)